

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁶ : A61F 2/06	A1	(11) International Publication Number: WO 96/33673 (43) International Publication Date: 31 October 1996 (31.10.96)
---	-----------	--

(21) International Application Number: PCT/US96/05815

(22) International Filing Date: 26 April 1996 (26.04.96)

(30) Priority Data:
08/429,897 27 April 1995 (27.04.95) US(71) Applicant: KHOURI BIOMEDICAL RESEARCH, INC.
[US/US]; 2 Kingsbury Place, St. Louis, MO 63112 (US).(72) Inventor: KHOURI, Roger, K.; 2 Kingsbury Place, St. Louis,
MO 63112 (US).(74) Agents: HOLLAND, Donald, R. et al.; Howell & Haferkamp,
Suite 1400, 7733 Forsyth Boulevard, St. Louis, MO 63105
(US).(81) Designated States: AU, CA, JP, European patent (AT, BE,
CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE).**Published**
With international search report.

(54) Title: DEVICE AND METHOD FOR VASCULAR ANASTOMOSIS



(57) Abstract

A temporary stent (12) and method for vascular anastomosis are disclosed. The method comprises placing, in a vessel (10) to be anastomosed, a stent (12) comprising a biocompatible material; applying staples (18) to anastomose the vessel (10); and converting the stent (12) material into a liquid that is miscible with blood by melting with warmed saline or pulsed radiation. Also disclosed is a method and composition for delivery of a drug that prevents thrombus formation and/or intimal hyperplasia at the anastomosis.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic			SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

DEVICE AND METHOD FOR VASCULAR ANASTOMOSISBackground of the Invention

(1) Field of the Invention

This invention generally relates to the field of reconstructive vascular surgery and, more particularly, to a device and method for vascular anastomosis.

5 (2) Description of the Related Art

Since the first successful vascular anastomosis was performed at the turn of the century, the search for an easier and faster technique than conventional needle-and-thread suturing has challenged surgeons. Payer was
10 the first to describe a technique for sutureless vascular anastomosis using a magnesium ring. (Metalles in den Chirurgie. Arch. Klin. Chir. 62:67, 1900). This principle was modified by Nakayama et al. and further modified by Østrup and Berggren into an apparatus for
15 microvascular anastomosis which is commonly used today. (Nakayama et al., Surgery 52:918-931, 1962; First Scandinavian Seminar on Reconstructive Microsurgery, Gothenburg, Sweden, October 1979, pp. 521-525, 1986. Although this apparatus has a number of advantages, it is
20 still far from the ideal vascular anastomosis device. The wall of the arteries is usually too thick and rigid to permit the necessary vessel eversion. This problem is even more severe in diseased vessels and limits the use of this device in vascular surgery. Furthermore, the
25 device is quite cumbersome and the surgical methods required for its use are difficult to master. Nonetheless, for lack of anything better, and because it saves operating time, the device is routinely used today in microvascular free flap surgery to anastomose veins.

30 An alternative to suturing the vessel, is the use of tiny staples or microvascular clips to bring vessel edges together circumferentially. (For example see Kirsch et al, The American Surgeon 12:722-727, 1992, which is incorporated herein by reference). Use of these staples
35 is, however, limited by the problem that in order to achieve accurate placement of the staples, eversion of

the edges of the vessel wall, and the avoidance of a "backwall" bite, an assistant is required to hold the vessel edges up while the staples are inserted. Not only is this inconvenient, such assistance is not always possible such as, for example, in endoscopic procedures.

The use of stents in vascular reconstruction can both facilitate the procedure itself and improve the outcome, particularly in small vessels and in veins. Temporary stents have been used in vascular surgery that are removed prior to complete closure of the anastomosis. These have been reported to improve the ease and rapidity of the anastomosis as well as decrease the danger of injury to the lumen and posterior wall and improve the percent of anastomoses remaining patent. (Wei et al., *British J Plastic Surg* 35:92-95, 1982, which is incorporated herein by reference). Soluble intravascular stents that dissolve and need not be removed have also been reported. Kamiji et al. used a polyethylene glycol stent that reportedly is washed away by the blood flow and dissolved after restoring blood flow. (*British J Plastic Surg* 42:54-58, 1989, which is incorporated herein by reference). In addition, stents have been reported that, upon completion of the anastomosis, can be melted or dissolved by warm isotonic saline and subsequently washed away in the blood on restoring blood flow (Cong et al, *Microsurgery* 12:67-71, 1991; Moskovitz et al, *Annals Plastic Surgery* 32:612-618, 1994, which are incorporated herein by reference). These groups used stents composed of a mixture of mono-, di-, and triglycerides that melt at temperatures near body temperature. Because the glycerides are normal elements in the blood stream, the stent was considered biocompatible.

Particular advantages reported on use of the stent with suturing of the anastomosis were an improvement in the accuracy and speed of the procedure, the minimizing of minor trauma, the avoidance of suture errors such as a

partial bite of the opposite wall, the achieving of a better coaptation of cut edges, the avoidance of narrowing at the anastomosis sites, the achieving of even distribution between stitches, and the preventing of vasospasm (Cong et al., 1991). Use of the stent with fibrin glue was reported to have the disadvantage of producing aneurysms. Although one group used the stent in combination with sutures, neither used the stents in combination with staples. Use of staples would be expected to reduce the likelihood of aneurysm formation compared to the use of fibrin glue because of the staples firmly holding the media in close enough apposition to allow proper healing over time. Furthermore, staples would be expected to decrease the time required for the procedure compared to use of suturing with the stent.

The use of a stent in combination with staples has not been appreciated as an advantage over the staples alone in open field microvascular anastomosis inasmuch as it has been reported that a stent is not necessary with microclip anastomosis (Kirsch et al, 1992). In the non-vascular anastomosis of vasovasostomy, an absorbable stent was used in combination with microvascular clips. (Gaskill et al, *Urology* 40:191-194, 1992, which is incorporated herein by reference). The stent was hollow and composed of polyglycolic acid. Furthermore, the stent was not immediately absorbable as would be required for such a temporary stent in a vascular anastomosis. This group reported that the combination of an absorbable stent with microclips allowed a shorter time for completion of the procedure (7.6 v. 8.5 minutes) and required less care. Nevertheless, it was indicated that there was no advantage to using the stent because of a high percentage of granulomas following its use apparently resulting from the need for more clips to seal the anastomosis or from obstruction of the stent. The requirement for more clips may indicate a failure of the

stent to fit snugly into the vessel. Furthermore, obstruction from the stent is likely to have been a result of the stent dissolving over a relatively long period of time. Moreover, this reference did not apply
5 the technique using the slowly absorbable stent along with stapling to vascular anastomosis.

Thus, in performing a vascular anastomosis, it would be desirable to have an improved method that is easy and rapid and that does not require an expert
10 surgical assistant and that also produces an eversion of the vessel edges and avoids a "backwall" bite.

One of the problems that can be associated with vascular anastomosis is the formation of thrombus at the anastomosis. The thrombus results from a gradual
15 accumulation of platelets at the anastomosis and the formation of fibrin. The thrombus thus formed could eventually occlude the vessel. It would be desirable, therefore, to provide some means to diminish the likelihood of formation of a thrombus at the anastomosis
20 site.

Summary of the Invention

In view of the limitations with existing methods, Applicant has succeeded in devising an improved device and method for vascular anastomosis. The method
25 comprises the steps of placing, in vessels to be anastomosed, a stent comprising a biocompatible material; applying staples to anastomose the vessels; and converting the stent material into a liquid that is miscible with blood by melting with warmed saline, pulsed
30 radiation or otherwise.

In accordance with the present invention, it has been discovered that utilization of a temporary stent for vascular anastomosis holds the vessel edges approximated together and stabilizes them while functioning as an
35 anvil against which the stapler can safely apply pressure without fear of catching the posterior wall. The stent

is also designed in a shape that tends to cause eversion of the vessel edges and facilitates approximation of intima to intima. The stent is made of a biocompatible material which is rapidly melted upon applying heat,
5 pulsed radiation such as laser energy or U.V. light, etc. and completely miscible with blood on flushing out the anastomosis by restoring blood flow.

Surprisingly, the method could be performed by a novice in substantially less time than the conventional
10 suture anastomosis could be performed by an expert. Furthermore, anastomoses performed using the stent with staples showed excellent approximation of the intimal edges and no significant anastomotic stenosis.

Thus the present invention provides the vascular
15 surgeon with new and improved procedure for performing vascular anastomosis that is faster and easier to perform and that provides an excellent outcome. This new method is particularly applicable to endoscopic procedures where the otherwise extremely difficult sutured anastomosis can
20 now be replaced with an easier, faster and safer anastomosis using staples available and well known in the art combined with a stent. In addition, the new method herein provides the vascular surgeon with an approach that can be used for end-to-side anastomoses by using a
25 T-shaped or Y-shaped stent.

Furthermore, the stent could also function as a drug delivery device. Thus, the present invention is also directed to a stent for use in vascular anastomosis comprising a substance that prevents thrombus formation
30 as well as to a method for preventing thrombus formation at a site of vascular anastomosis in an individual comprising administering to the individual a substance that prevents thrombus formation. The incorporation of the drug into the stent would allow a continuous release
35 of the drug once placed in the lumen during the anastomosis procedure. Then upon melting and dissolving

or emulsifying the anastomosis, the drug within the stent would be immediately released.

Among the several advantages found to be achieved by the present invention, therefore, may be noted the provision of a method of vascular anastomosis for improved accuracy and speed compared to use of the stent alone or with suturing or compared to stapling alone; the provision of a method of vascular anastomosis that avoids the danger of injury to the lumen or posterior wall from the staples; and the provision of a method and device for vascular anastomosis that utilize a stent to deliver a bioactive drug to prevent undesirable complications such as the formation of thrombus or intimal hyperplasia.

While the principal advantages and features of the present invention have been described above, a more complete and thorough understanding of the invention may be attained by referring to the drawings and description of the preferred embodiment which follow.

Brief Description of the Drawings

The drawing illustrates use of the stent and staples of the present invention in vascular anastomosis.

Description of Preferred Embodiments

As shown in the figure, a stent 12 is placed in the lumen of vessel 10. The stent has an oval shape in which the longitudinal axis length is greater than the transverse axis length. Thus, there is a lengthwise tapering from the center to the end. This design effectively causes an eversion of the edges 14 of the vessel 10 to facilitate approximation of the intima 16 of each of the two edges. This is explained in greater detail, infra. Staple 18 pinches together the edges 14 of the vessel 10 bringing together the intima 16.

The stent material as placed in the lumen of the vessels is solid and must be of sufficient strength to be able to act as an anvil against which the staples are applied. By applying the staples against the stent, the

BAD ORIGINAL

likelihood of penetration of the staple into the lumen and injury to the inner lining of the vessel wall is diminished. Furthermore, the stent prevents a deeper penetration to the posterior wall on opposite side of the vessel lumen thus precluding backwall injury.

The stent can be made up of any solid material, which upon completion of the anastomosis, can be rapidly melted or dissolved and that is readily miscible with blood upon restoring flow through the anastomosis.

10 The melting or dissolving of the stent can be accomplished by any suitable means, for example by irrigating the operative field with warmed saline. Alternatively, the stent material can be melted by pulsed radiation such as with a laser, U.V. light, or by any
15 other means that can convert the solid stent material into a liquid.

Examples of stent materials useful in the present invention are mixtures of mono-, di- and triglycerides, polyglycolic acids and polyethylene glycol. The stent
20 materials are readily miscible with blood either by virtue of being water soluble or by being readily able to form an emulsion or dispersion with blood. Polyethylene glycol 1500, which is water soluble and melts between 44°C and 48°C is an example of stent material useful in
25 the present invention. A preferred stent material is a mixture of mono-, di- and triglycerides that consists mostly of triglycerides with diglycerides present in a concentration of 1% or less and monoglycerides present in a concentration of 1% or less. This mixture is sold
30 under the trademark WITEPSOL® and the manufacturer's identification H 37 (Hüls, AG, Witten, Germany; Hüls America, Piscataway, N.J.). WITEPSOL® H 37 comprises glycerol esters of vegetable saturated fatty acids, mainly lauric acid prepared from coconut and palm kernel
35 oils. (See Hüls WITEPSOL® product bulletin which is incorporated by reference). It is a solid with a melting

point between 36°C and 38°C. Saline warmed to approximately 45°C rapidly melts this material.

The stent material must also be biocompatible. In addition, the liquid stent material by virtue of being
5 readily dissolved, emulsified or dispersed in the blood, produces no deleterious effect upon restoring blood flow and flushing from the anastomosis.

The stent materials disclosed above are exemplary only and the skilled artisan will appreciate that stents
10 within the scope of this invention can be comprised of any suitable material that satisfies the criteria set forth above.

Methods for preparation of stents are well known in the literature. (See for example Cong et al.,
15 *Microsurgery* 12:67-71, 1991; Moskovitz et al, *Ann Plastic Surg* 32:612-618, 1994; Kamiji et al., *Brit J Plastic Surg* 42:54-58, 1989, which are incorporated herein by reference). Stents can be fabricated in virtually any desired size, although the shape and size depicted in the
20 preferred embodiment has been found to be particularly helpful in everting the vessel sidewalls.

The stent for use in anastomosis of a particular vessel is selected so that it will fit snugly inside the lumen of that vessel. As shown in the figure, as the
25 stent is inserted into the vessel, its sidewalls eventually contact the stent and are angled obliquely, or radially outward. After insertion into both ends, the vessel sidewalls contact each other obliquely and are readily everted upon further advance.

30 Staple, 18, can be any of a number well known in the art and devices for applying staples are also well known in the art. (See for example Kirsch et al, *Am Surgeon* 58:722-727, 1992; Tredway et al., *Fertil Steril* 62:624-629, 1994, which are incorporated herein by
35 reference). The staples can be made of any biocompatible material such as, for example, titanium. The size of the

stables is selected according to the wall thickness of the vessel being anastomosed and the jaw opening can be in the range of from approximately 0.3 mm to approximately 2 mm. The present invention is applicable to anastomosis of vessels of virtually any size including vessels as large as the abdominal aorta as well as vessels as small as 1 mm in diameter and smaller. The methods and compositions herein are also applicable to both arteries and veins.

10 Vascular anastomosis performed by the present improved procedure is faster and easier to perform while providing an excellent outcome. Because of this, the present improved method facilitates the performance of otherwise extremely difficult anastomosis procedures.

15 For example, the present invention provides a practical method for endoscopic vascular surgery. The method can also be used with L-shaped or T-shaped stents for use in end-to-side anastomosis. This provides a practical method for coronary artery bypass grafts where an end-to-

20 side anastomosis is desired.

The stent can also act as a means to locally deliver bioactive agents that have beneficial effects upon the anastomosis. The incorporation of a drug into the stent would allow local release of the drug during

25 the anastomosis procedure and particularly upon the melting and dissolution or emulsion of the stent inside the anastomosis. This provides a very practical method for direct delivery of the drug to the anastomosis. One example of such a bioactive agent that can be

30 incorporated into the stent for delivery to the anastomosis is recombinant Tissue Factor Pathway Inhibitor (TFPI). TFPI reduces the buildup of thrombus at the anastomosis, improves the patency rate of the vascular anastomosis (Khoury et al., U.S. Patent No.

35 5,276,015 which is incorporated by reference). The inventor also believes that TFPI can reduce the amount of

intimal hyperplasia which develops at vascular anastomoses. The incorporation of such an agent into the stent material would represent an ideal method of local drug delivery.

5 The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only and are not intended to be limiting unless otherwise
10 specified.

EXAMPLE 1

The preparation of stents is illustrated in the method used for making the 10 mm stents.

15 Stents having a diameter of 10 mm were fabricated from 1 g WITEPSOL® H 37. WITEPSOL® H 37 is a solid with a melting point between 36 and 38°C. It is widely used in pharmaceuticals for drug delivery. The pastilles were carefully warmed up to 45°C in a water bath and the
20 resulting clear fluid brought into silicone molds. The molds were in a generally oval shape providing a tapering of the two ends of the stent. The material was allowed to cool down and harden at room temperature. The stents were removed from the mold, gas sterilized and stored at -20°C. On the day of surgery, the stents were kept in an
25 ice-saline bath until they are inserted into the vessel ends.

Example 2

30 This example illustrates the method of anastomosis of large and small vessel using the abdominal aorta and small arteries in pigs and rabbits.

 In 5 American farm pigs (30kg), a median laparotomy was performed and the abdominal aorta was dissected transperitonially and divided between vascular clamps. A 10 mm stent of WITEPSOL® H 37 (1 g) was
35 inserted into the divided vessel stumps. The shape of the stent was such that it caused a slight eversion of

the edges and facilitated intimal approximation. In the first experiment the anastomosis was performed by applying approximately 20 staples with Endopath EAS. In the following 4 experiments, the anastomoses were

5 performed with Endopath EMS and a smaller number of staples was required. The experiments were performed by the operator alone, without an assistant holding the vessel edges. At the completion of the anastomoses, the operative field was irrigated with warm saline (45°C)

10 until the stent completely dissolved (10-15 seconds). The clamps were released and the anastomoses were observed for 60 minutes. The animals were sacrificed with an overdose of barbiturates and a lead oxide angiography was performed. The abdominal aorta,

15 including the anastomosis was then resected and submitted for histological evaluation.

Abdominal aortas (3mm), carotid arteries (2mm), and central ear arteries (1mm), were dissected in New Zealand white rabbits and divided between vascular

20 clamps. In 5 animals a conventional sutured anastomosis was performed by a single experienced microsurgeon without an assistant. In 5 animals a stented and stapled anastomosis was performed by a single novice microsurgeon without an assistant and without prior experience with

25 the use of the stapler. To perform the stented and stapled anastomosis, the vessels were approximated over the stent and held together by applying 8 microstaples around the circumference. The stents were made of an inert triglyceride compound (WITEPSOL® H 37), which melts

30 at body temperature. They were designed such that they fitted snugly inside the lumen and caused an eversion of the edges to facilitate intimal approximation. At the completion of the anastomoses, the vessels were irrigated with warm saline (45°C) until the stents completely

35 dissolved (10-15 seconds), and the clamps were then released. The time taken to complete the anastomosis

(clamp on/clamp off), and one day and one week patency were recorded. Angiograms were performed and the vessels were perfusion fixed at one week to determine the presence of anastomotic stenosis. Using T-shaped stents, 5 end-to-side anastomoses were performed and compared with similar sutured anastomoses.

All anastomoses were patent at one day and one week. The average time taken by the novice to perform the stapled anastomosis alone was 2.5 minutes. In 10 contrast, it took the experienced vascular surgeon 9 minutes to perform the sutured anastomoses ($p < 0.01$). All the stapled anastomoses had excellent approximation of the intimal edges without significant anastomotic stenosis. There was no observable side effect from the 15 stent material.

These experiments demonstrate the stapled vascular anastomosis using a soluble intraluminal stent that acts as an anvil. The presence of a stent made the stapling very practical and simple. The stent is made up of a 20 solid material which can dissolve on command at the completion of the anastomosis. There were no observed deleterious effects from the bolus of lipid infusion which resulted when the lipid stent dissolved, although other potential materials could be found which can become 25 soluble by pulsed radiation or other physical means.

In view of the above, it will be seen that the several objects of the invention are achieved and other advantageous results attained.

As various changes could be made in the above 30 constructions without departing from the scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense.

What is Claimed is:

1. A method for vascular anastomosis in a subject comprising the steps of:

- 5 (a) placing, in a vessel to be anastomosed, a stent comprising a biocompatible material;
(b) applying staples to anastomose the vessel; and
(c) converting the stent material into a liquid that is miscible with blood.

2. The method according to claim 1 wherein the stent material melts upon applying heat and the step of converting the material to a liquid includes the step of applying heat.

3. The method according to claim 2 wherein the step of applying heat includes the step of irrigating the operative field with warmed saline.

4. The method according to claim 3 wherein the stent comprises a material selected from the group consisting of a mixture of monoglycerides, diglycerides and triglycerides; a polyglycolic acid; a polyethylene glycol; and mixtures thereof.

5 5. The method according to claim 4 wherein the stent material comprises WITEPSOL® H 37.

6. The method according to claim 1 wherein the stent material melts on applying pulsed radiation and the step of converting the material to a liquid includes the step of applying pulsed radiation.

7. The method according to claim 6 wherein the stent comprises a material selected from the group consisting of a mixture of monoglycerides, diglycerides and triglycerides; a polyglycolic acid; a polyethylene glycol; and mixtures thereof.

8. The method according to claim 1 wherein the anastomosis is an end-to-end anastomosis and the stent has a center and two opposite ends, and a lengthwise tapering from the center to each end.

9. The method according to claim 1 wherein the anastomosis is an end-to-side anastomosis and the stent is in an L-shape, a T-shape or a Y-shape.

10. The method according to claim 1 wherein the stent contains a substance that prevents thrombus formation and/or intimal hyperplasia.

11. The method according to claim 10 wherein the substance that prevents thrombus formation and/or intimal hyperplasia comprises Tissue Factor Pathway Inhibitor (TFPI).

12. A temporary stent for use in vascular anastomosis comprising a biocompatible material that can be converted to a liquid that is miscible with blood and a substance that prevents thrombus formation and/or
5 intimal hyperplasia.

13. The stent according to claim 12 wherein the stent is comprised of a material which will convert to liquid upon application of heat or pulsed radiation.

14. The stent according to claim 13 wherein the substance that prevents thrombus formation and/or intimal hyperplasia is released from the stent material upon converting to the liquid.

15. The stent according to claim 12 wherein the substance that prevents thrombus formation and/or intimal hyperplasia comprises TFPI.

16. A method for preventing thrombus formation and/or intimal hyperplasia at a site of vascular anastomosis in an individual comprising administering to the individual a substance that prevents thrombus
5 formation and/or intimal hyperplasia.

17. The method of claim 16 wherein the substance that prevents thrombus formation and/or intimal hyperplasia is administered at the site of vascular anastomosis.

18. The method according to claim 17 wherein the substance that prevents thrombus formation and/or intimal

hyperplasia is released from a stent at the site of vascular anastomosis.


19. The method according to claim 18 wherein the substance that prevents thrombus formation and/or intimal hyperplasia is TFPI.

20. The method according to Claim 1 wherein the step of placing the stent includes the step of everting the vessel sidewalls as the stent is advanced into the vessel.

21. The method according to Claim 20 wherein the stent has a portion with a cross-sectional area sized to fit snugly within said vessel.

22. The method according to Claim 21 wherein the stent has a center and two opposite ends, and a lengthwise tapering from the center to each end, said center comprising said snugly fitting portion.

23. A temporary stent for use in vascular anastomosis comprising a biocompatible material that can be converted to a liquid that is miscible with blood, said stent having a pair of opposing tapered surfaces
5 which meet at a center, said center having a cross-sectional area sized to fit snugly within said vessel so that said vessel sidewalls are everted as said stent is inserted in said vessel.



INTERNATIONAL SEARCH REPORT

 International application No.
PCT/US96/05815

A. CLASSIFICATION OF SUBJECT MATTER

 IPC(6) : A61F 2/06
US CL : 623/1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 128/898; 606/154, 194; 623/1, 6, 12, 15

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y --- A	THE AMERICAN SURGEON, December 1991, Vol. 58, No. 12, (KIRSCH ET AL.) A New Method for Microvascular Anastomosis: Report of Experimental and Clinical Research, pages 722-727.	1-11, 20-23 ----- 12-19
Y --- A	US, A, 5,141,516 (DETWEILER) 25 August 1992, see column 1 lines 8-12, column 2 lines 5-10, column 4 lines 8-11, column 7 lines 20-23, column 5 lines 1-35, and Fig. 2.	1-11, 20-23 ----- 12-19
Y	US, A, 4,770,176 (MCGREEVY ET AL.) 13 September 1988, see column 4 lines 41-54.	2-7, 12-19

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

26 JUNE 1996

Date of mailing of the international search report

19 JUL 1996

 Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3590

Authorized officer

FRANCIS K. CUDDIHY

Telephone No. (703) 308-2996

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/05815

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y --- A	Wiley-Liss, Inc., 1991, (CONG ET AL.) EXPERIMENTAL STUDY ON MICROVASCULAR ANASTOMOSIS USING A DISSOLVABLE STENT SUPPORT IN THE LUMEN, Dept. of Orthopaedic Surgery, Air Force Hospital, No. 1, Gongnongyuan Street, Chengau, Sichuan, People's Republic of China 610061, pp.67-71.	3-5 ----- 12-19
Y --- A	Annals of Plastic Surgery, Volume 21/Number 6/June 1994, (MOSKOVITZ ET AL.) Microvascular Anastomoses Utilizing New Intravascular Stents, 180 Clinton St., Brooklyn, NY 11201, pp.612-618.	3-5 ----- 12- 19
Y --- A	British Journal of Plastic Surgery (1989), The Trustees of British Association of Plastic Surgeons, (T. KAMIJI ET AL.) Microvascular anastomosis using polyethylene glycol 4000 and fibrin glue, pp.54-58.	3-5 ----- 12-19
Y --- P A	US, A, 5,464,450 (BUSCEMI ET AL.) 07 November 1995, see column 5 lines 10-20.	4, 5, 7, 9-11 ----- 12-19
Y	US, A, 5,276,015 (KHOURI ET AL.) 04 January 1994, see column 2 lines 42-49.	11
Y	US, A, 3,908,662 (RAZGULOV ET AL.) 30 September 1975, see column 5 lines 23-27, and column 10 lines 32-44.	20-23

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.